

תאריך: 6.11.2014.

שם תכשיר באנגלית ומספר הרישום:

Sandostatin LAR 10mg 112-50-29488-00

Sandostatin LAR 20mg 112-50-29489-00

Sandostatin LAR 30mg 112-50-29490-00

שם בעל הרישום: Novartis Pharma Services AG.

טופס זה מיועד לפרוט החמרות בלבד !

ההחמרות המבוקשות												
טקסט חדש	טקסט נוכחי	פרק בעלון										
<p>...</p> <p>Cardiovascular related events</p> <p>Uncommon – cases of bradycardia have been reported (frequency: common).</p> <p>...</p>	<p>...</p> <p>Cardiovascular related events</p> <p>Uncommon cases of bradycardia have been reported.</p> <p>...</p>	6 Warnings and precautions										
<p>...</p> <p>Glucose metabolism</p> <p>... Hypoglycemia has also been reported.</p> <p>...</p>	<p>...</p> <p>Glucose metabolism</p> <p>...</p>	6 Warnings and precautions										
<p>...</p> <p>Table 7-1 Adverse drug-Drug reactions Reactions reported-Reported in clinical Clinical studies-Studies</p> <p>...</p> <table border="1"> <tr> <td colspan="2">General disorders and administration site disorders/conditions:</td> </tr> <tr> <td>Very common:</td> <td>Injection site localized pain-reaction</td> </tr> <tr> <td>Common:</td> <td>Asthenia</td> </tr> </table> <p>...</p>	General disorders and administration site disorders/conditions:		Very common:	Injection site localized pain-reaction	Common:	Asthenia	<p>...</p> <p>Table 1 Adverse drug reactions reported in clinical studies</p> <p>....</p> <table border="1"> <tr> <td colspan="2">General disorders and administration site disorders:</td> </tr> <tr> <td>Very common:</td> <td>Injection site localized pain</td> </tr> </table> <p>....</p>	General disorders and administration site disorders:		Very common:	Injection site localized pain	7 Adverse drug reactions
General disorders and administration site disorders/conditions:												
Very common:	Injection site localized pain-reaction											
Common:	Asthenia											
General disorders and administration site disorders:												
Very common:	Injection site localized pain											
<p>...</p> <p><u>Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance may be necessary when Sandostatin LAR is administered concomitantly (see section 6 Warnings and precautions).</u></p>	<p>...</p>	8 Interactions										

ההחמרות המבוקשות

Dose adjustments of insulin and antidiabetic medicinal products may be required when Sandostatin LAR is administered concomitantly (see section 6 Warnings and precautions).

...

מצ"ב העלון, שבו מסומנות ההחמרות המבוקשות **על רקע צהוב**. שינויים שאינם בגדר החמרות סומנו (בעלון) בצבע שונה. יש לסמן רק תוכן מהותי ולא שינויים במיקום הטקסט.

הועבר בדואר אלקטרוני בתאריך 6 בנובמבר, 2014

.....